EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study

Xueqing Ma, Yonghua He, Panpan Shao, Ling Guo, Wenpei Liang, Jianhua Zhou, Huiqing Yuan, Liru Qiu

Pediatric Rheumatology · 21.10.2025 · 23 (1)

DOI: 10.1186/s12969-025-01159-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pediatric Rheumatology, online erschienen am 21.10.2025. Verfasst von Xueqing Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Resea…. Hauptthemen laut MEDLINE: Immunoglobulin A, IgA Vasculitis, Vasculitis, Glomerulonephritis, IGA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Provincial Health Committee General Program, Beijing Medical Award Foundation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunoglobulin A vasculitis (IgAV) is the most common childhood vasculitis and can lead to immunoglobulin A vasculitis nephritis (IgAVN) in severe cases, potentially progressing to kidney failure in a subset of children. Safer and more effective treatments are needed to improve outcomes in these children. This study aimed to evaluate the efficacy and safety of telitacicept in the treatment of children with IgAV and IgAVN.

Methods

This is a single-center, retrospective observational study of twenty four children with IgAV or IgAVN who received telitacicept treatment, and thirty matched children with IgAVN who only received conventional treatment were taken as the control group for children with IgAVN who received telitacicept treatment in acute phase. The treatment response was evaluated through urine protein, serum albumin, eGFR and serum immunoglobulin levels, and data was analyzed at telitacicept initiation and at 4, 12, 24 and 36 weeks after treatment.

Results

A total of twenty four children (thirteen boys and eleven girls) with IgAV ( n = 5) and IgAVN ( n = 19, comprising ten acute and nine chronic cases) were enrolled. All children with IgAV experienced improvement of skin, joint, and gastrointestinal symptoms after telitacicept treatment, with no kidney involvement during follow-up. In children with IgAVN, the urinary protein-to-creatinine ratio (UPCR) significantly decreased at 36 weeks compared to baseline ( P < 0.05) in both acute and chronic groups, while estimated glomerular filtration rate (eGFR) remained stable ( P > 0.05). In addition, the dose of steroids administered during the treatment with telitacicept was significantly reduced, the acute IgAVN group exhibited significantly greater steroid reduction between weeks 4 and 24 compared with the controls group ( P < 0.05). Furthermore, serum immunoglobulin levels (IgA, IgG) significantly decreased 12 weeks after telitacicept treatment ( P < 0.01), and no other adverse reactions observed.

Conclusion

Telitacicept appears to be a promising therapy for children with IgAV and IgAVN, effectively inducing proteinuria remission, improving systemic symptoms, and reducing the use of steroids, with favorable safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin AIgA VasculitisVasculitisGlomerulonephritis, IGANephritisHumansMaleFemaleRetrospective StudiesChildTreatment OutcomeAdolescentChild, PreschoolRecombinant Fusion Proteins

Stichwörter der Autor:innen

ChildrenIgA vasculitisIgA vasculitis nephritisTalitacicept

Substanzen

Immunoglobulin AtelitaciceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Research Center for Children's Growth and Development and Metabolic Disease…

Förderung

  • Hubei Provincial Health Committee General Program
  • Beijing Medical Award Foundation Program

Zitieren

APA

Ma, X., He, Y., Shao, P., Guo, L., Liang, W., Zhou, J., Yuan, H., & Qiu, L. (2025). Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study. Pediatric Rheumatology, 23(1). https://doi.org/10.1186/s12969-025-01159-3

Vancouver

Ma X, He Y, Shao P, Guo L, Liang W, Zhou J, et al. Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study. Pediatric Rheumatology. 2025;23(1). doi:10.1186/s12969-025-01159-3

BibTeX
@article{Ma2025,
  author = {Ma, Xueqing and He, Yonghua and Shao, Panpan and Guo, Ling and Liang, Wenpei and Zhou, Jianhua and Yuan, Huiqing and Qiu, Liru},
  title = {Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study},
  journal = {Pediatric Rheumatology},
  year = {2025},
  volume = {23},
  number = {1},
  doi = {10.1186/s12969-025-01159-3}
}
Kostenlos starten →